Neuroleptic-Induced Akathisia

Neuroleptic-induced akathisia is a common, distressing extrapyramidal syndrome characterized by subjective inner restlessness and objective psychomotor agitation, occurring in up to 20–50% of patients on antipsychotics depending on the agent used. [1-2] It is frequently underdiagnosed and undertreated, and can lead to medication nonadherence, worsening psychosis, aggression, and suicidality. [3-4]

• Key HPI questions: When did the restlessness start? Was there a recent medication change (new antipsychotic, dose increase, antiemetic)? What is the temporal relationship to the offending drug?
• Symptom characterization: Inner sense of restlessness, "can't sit still," urge to move — especially in the legs. Patients may describe it as anxiety, tension, or dysphoria rather than a movement problem. [1][3]
• Timing: Acute akathisia typically begins within hours to days of initiating or increasing a dopamine receptor blocking agent, with 50% of cases occurring within the first month. [1]
• Triggers: Dose escalation, rapid titration (especially risperidone), switching agents, or withdrawal of anticholinergics. [3][5]
• Severity/progression: Ask whether symptoms are constant or intermittent, whether movement provides relief, and whether the patient has had thoughts of self-harm.
• Important negatives: No circadian worsening at night (distinguishes from RLS), no premonitory urge limited to sleep onset, no history of similar symptoms before medication exposure. [6]

• Suicidal ideation or self-harm: Akathisia is associated with dysphoria, irritability, aggression, and suicide attempts — particularly in first-episode schizophrenia. One study found suicidal thoughts in 46% and suicide attempts in 38% of patients with akathisia. [3][7-9]
• Paradoxical worsening of psychosis shortly after antipsychotic initiation — may prompt a dose increase that further exacerbates akathisia. [1]
• Severe agitation or violence: Behavioral dyscontrol and heteroaggressivity are reported complications. [4][9]
• Inability to maintain any position for more than a few seconds indicates severe akathisia requiring urgent intervention. [3]

Causative agents (by risk)

• Highest risk: Haloperidol (~50% incidence), first-generation antipsychotics (FGAs) [1]
• Moderate risk: Aripiprazole, asenapine, lurasidone, risperidone [1]
• Lower risk: Quetiapine, olanzapine (~4%) [1]
• Non-antipsychotic causes: Metoclopramide, prochlorperazine, SSRIs, SNRIs, TCAs, calcium channel blockers, tetrabenazine [3][10]

Treatment agents (evidence-based, "B-CALM" mnemonic): [11]

• Beta-blockers: Propranolol 20–80 mg/day — first-line; lipophilic beta-blockers preferred [2][12-13]
• Clonazepam/benzodiazepines: Clonazepam 0.5–2.5 mg/day for subjective distress [2][14]
• Anticholinergics: Biperiden 6 mg/day (evidence from network meta-analysis); benztropine less studied for akathisia specifically [13]
• cLonidine: Alpha-2 agonist, third-line option [2]
• Mirtazapine: 7.5–15 mg/day — strongest evidence among 5-HT2A antagonists [12-13]

Other agents with evidence: Vitamin B6 600–1200 mg/day, trazodone 50 mg/day, mianserin 15 mg/day, cyproheptadine 4 mg q12h. [13][15-16]

Contraindications/cautions

• Propranolol: contraindicated in asthma, decompensated HF, severe bradycardia; monitor for orthostatic hypotension [12]
• Benzodiazepines: sedation, dependence risk, respiratory depression
• Anticholinergics: dry mouth, urinary retention, cognitive impairment — use cautiously in elderly [17]
• Do NOT increase the antipsychotic dose — this worsens akathisia [1][3]

• Iron-rich diet may be considered given the association between low iron/ferritin and akathisia risk. Ensure adequate dietary iron intake (red meat, leafy greens, legumes). [18-19]
• Caffeine reduction — may exacerbate subjective restlessness and anxiety.
• No specific acute dietary intervention is established.

• Psychiatric: Mood changes, dysphoria, irritability, anxiety, suicidal ideation, insomnia, worsening psychotic symptoms [3][9]
• Neurological: Tremor, rigidity, gait changes (concurrent drug-induced parkinsonism), involuntary movements (tardive dyskinesia) [17]
• Cardiovascular: Palpitations, orthostatic symptoms (relevant if starting propranolol)
• Sleep: Insomnia, restless sleep (distinguish from RLS)
• GI: Nausea, appetite changes (relevant if antiemetic-induced)

• Collateral: Confirm medication timeline, recent dose changes, and observed restless behaviors from nursing staff, family, or caregivers. Patients with psychosis may have difficulty articulating subjective symptoms. [4]
• Family history: Family history of RLS (to distinguish), movement disorders, or iron deficiency anemia.
• Social context: Assess medication adherence — akathisia is a leading cause of antipsychotic nonadherence. Evaluate for substance use (cocaine intoxication, opioid withdrawal can mimic akathisia). [3][20]

• Drug-related: High-potency FGAs, rapid dose titration, higher doses, polypharmacy with multiple dopamine-blocking agents [5][21]
• Patient-related: Iron deficiency (lower serum iron and ferritin levels associated with akathisia), older age, female sex (for chronic/tardive forms) [18-19][22]
• Comorbid: Drug-induced parkinsonism (significantly correlated with akathisia), negative symptoms, cognitive dysfunction, affective disorder diagnosis [21-22]
• Rapid initiation of risperidone significantly increases akathisia risk (HR 6.47) [5]

• Restless legs syndrome (RLS): Worse at night, relieved by movement, urge localized to legs, family history common, no temporal association with dopamine-blocking agents [6]
• Generalized anxiety disorder / agitation: No stereotyped motor pattern, no temporal medication relationship; patients with prior anxiety can often distinguish akathisia as "different" [3]
• Tardive dyskinesia: Orofacial choreiform movements predominate; increasing antipsychotic dose temporarily relieves TD but worsens akathisia [3]
• Drug-induced parkinsonism: Bradykinesia, rigidity, tremor — can coexist with akathisia [17]
• Psychotic agitation / manic episode: Driven by thought content, not inner restlessness [3]
• Substance intoxication (stimulants) or withdrawal (opioids): History and toxicology distinguish [3][20]
• Akathisia of Parkinson's disease or iron-deficiency anemia: Phenomenologically similar but no medication temporal relationship [3]

• Prior episodes of akathisia or extrapyramidal symptoms with antipsychotics
• History of iron deficiency anemia
• Parkinson's disease or other movement disorders
• Psychiatric diagnosis (schizophrenia, bipolar disorder, depression)
• Prior antipsychotic trials and tolerability
• History of substance use disorders (opioid use — withdrawal mimics akathisia)

Vital signs: Tachycardia may be present; obtain baseline HR and BP before starting propranolol.

Focused exam

• Observation at rest: Rocking while seated, crossing/uncrossing legs, fidgeting, inability to remain seated [1][3]
• Observation standing: Shifting weight foot to foot, marching in place, pacing [3]
• Gait: Decreased arm swing may suggest concurrent drug-induced parkinsonism [17]
• Orofacial exam: Tongue protrusion, lip smacking, jaw movements → suggests tardive dyskinesia rather than akathisia [23]
• Tone/rigidity: Cogwheel rigidity suggests concurrent parkinsonism
• Ask the patient to sit still for 2 minutes and observe for restless movements — this is a key diagnostic maneuver [24]

• Serum iron, ferritin, TIBC: Lower iron and ferritin levels are associated with akathisia; correct iron deficiency if present [18-19]
• CBC: Evaluate for anemia
• CMP: Baseline renal/hepatic function (relevant for medication dosing)
• TSH: Rule out hyperthyroidism as a cause of restlessness
• Urine drug screen: Rule out stimulant intoxication or opioid withdrawal
• No specific lab test confirms akathisia — it remains a clinical diagnosis [3]

• Not routinely indicated. Akathisia is a clinical diagnosis.
• Consider brain MRI only if atypical features suggest structural pathology (e.g., focal neurological deficits, new-onset movement disorder without medication exposure).

Barnes Akathisia Rating Scale (BARS) — the most widely used validated tool: [24-25]

• Rates objective restlessness (0–3), subjective awareness of restlessness (0–3), subjective distress (0–3), and a global clinical assessment (0–5)
• Global score: 0 = absent, 1 = questionable, 2 = mild, 3 = moderate, 4 = marked, 5 = severe
• Should be administered before starting antipsychotics and during dose titration as a baseline and monitoring tool [26]

Other scales: Simpson-Angus Scale (for concurrent parkinsonism), AIMS (for tardive dyskinesia). [27]

• Obtain baseline ECG before starting propranolol (assess for bradycardia, heart block)
• Evaluate QTc if the patient is on QT-prolonging antipsychotics (haloperidol, ziprasidone)
• No specific ECG pattern for akathisia itself
• Monitor for sinus bradycardia after initiating beta-blocker therapy

• Akathisia is a clinical diagnosis based on temporal relationship to a dopamine-blocking agent, subjective inner restlessness, and characteristic motor patterns. [3]
• Severity stratification using the BARS global score guides management intensity. [24]
• Typical presentation: Onset within days to weeks of starting/increasing an antipsychotic; patient reports "can't sit still," with observable rocking, pacing, or leg movements.
• Atypical presentations: Purely subjective akathisia without visible motor signs; akathisia presenting as worsening psychosis or aggression (may be misinterpreted as inadequate antipsychotic dosing). [1][4]
• Complications: Medication nonadherence, exacerbation of psychosis, suicidality, violence, and prolonged hospitalization. [3-4][9]

Key clinical pearl: The most dangerous pitfall is misdiagnosing akathisia as psychotic agitation and increasing the antipsychotic dose, which creates a vicious cycle of worsening symptoms. [1]

Step 1 — Reduce or eliminate the offending agent: [26]

• Dose reduction of the current antipsychotic
• Discontinue antipsychotic polypharmacy if applicable
• Switch to a lower-risk agent (quetiapine, olanzapine) [1][26]

Step 2 — Pharmacologic rescue (if dose change not feasible):

Step 3 — Refractory cases: Consider clonidine, gabapentin/pregabalin, amantadine, or rotation between agents. [2][10]

Correct iron deficiency if ferritin is low. [18]

• Discharge criteria: Mild akathisia (BARS global ≤2), no suicidal ideation, stable psychiatric status, outpatient follow-up arranged, rescue medication prescribed
• Observation/admission: Moderate-severe akathisia with suicidal ideation, aggression, inability to tolerate oral medications, or need for antipsychotic adjustment in a monitored setting
• Specialist consultation triggers:
  • Psychiatry: For antipsychotic switching, refractory akathisia, or concurrent psychotic decompensation
  • Neurology: If diagnostic uncertainty (e.g., concern for tardive dyskinesia, Parkinson's disease, or other movement disorder)

• Follow-up timing: Within 48–72 hours if discharged with a new rescue medication; within 1 week for medication adjustment
• Return precautions — instruct patient/family to return immediately for:
  • Suicidal thoughts or self-harm urges
  • Worsening agitation, aggression, or inability to stay still
  • Medication side effects (e.g., dizziness, fainting, severe sedation from propranolol or benzodiazepines)
  • New involuntary movements (tongue, face, limbs) suggesting tardive dyskinesia
• Patient counseling: Akathisia is a medication side effect, not a worsening of the underlying psychiatric illness. It is treatable and typically resolves with medication adjustment. Do not stop antipsychotics abruptly without medical guidance (risk of withdrawal akathisia). [1-2]
• Expected recovery: Acute akathisia generally resolves within days to weeks of dose reduction or switching, though chronic and tardive forms may persist. [2][10]

1. Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture. — Factor SA, Burkhard PR, Caroff S, et al. The Lancet. Neurology. 2019.

2. Managing Antipsychotic-Induced Acute and Chronic Akathisia. — Miller CH, Fleischhacker WW. Drug Safety. 2000.

3. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.

4. The Clinical Challenges of Akathisia. — Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. CNS Spectrums. 2015.

5. Incidence and Predictors of Acute Akathisia in Severely Ill Patients With First-Episode Schizophrenia Treated With Aripiprazole or Risperidone: Secondary Analysis of an Observational Study. — Yoshimura B, Sato K, Sakamoto S, et al. Psychopharmacology. 2019.

6. Restless Legs Syndrome. — Winkelman JW, Wipper B. The Journal of the American Medical Association. 2026.

7. The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review. — Kalniunas A, Chakrabarti I, Mandalia R, Munjiza J, Pappa S. Neuropsychiatric Disease and Treatment. 2021.

8. Akathisia and Suicidal Ideation in First-Episode Schizophrenia. — Seemüller F, Schennach R, Mayr A, et al. Journal of Clinical Psychopharmacology. 2012.

9. Akathisia Among Patients Undergoing Antipsychotic Therapy: Prevalence, Associated Factors, and Psychiatric Impact. — Jouini L, Ouali U, Ouanes S, et al. Clinical Neuropharmacology. 2022.

10. Pathophysiology and Management of Akathisia 70 Years After the Introduction of the Chlorpromazine, the First Antipsychotic. — Zareifopoulos N, Katsaraki M, Stratos P, et al. European Review for Medical and Pharmacological Sciences. 2021.

11. Struggling to Find Effective Pharmacologic Options for Akathisia? B-Calm!. — Thippaiah SM, Fargason RE, Birur B. Psychopharmacology Bulletin. 2021.

12. Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-Ht Receptor Antagonists. — Poyurovsky M, Weizman A. Drugs. 2020.

13. Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis. — Gerolymos C, Barazer R, Yon DK, et al. JAMA Network Open. 2024.

14. Comparative Efficacy of Akathisia Treatments: A Network Meta-Analysis. — Gambolò L, Bottignole D, D'Angelo M, Bellini L, Stirparo G. CNS Spectrums. 2024.

15. Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis. — Furukawa Y, Imai K, Takahashi Y, Efthimiou O, Leucht S. Schizophrenia Bulletin. 2026.

16. Evaluating the Effectiveness of Cyproheptadine on Acute Neuroleptic-Induced Akathisia: A Double-Blind Randomized Controlled Trial. — Shams-Alizadeh N, Maroufi A, Rahmani K, Majidi S, Moghadam M. Journal of Clinical Psychopharmacology. 2026.

17. Schizophrenia. — Marder SR, Cannon TD. The New England Journal of Medicine. 2019.

18. Iron Homeostasis Alterations and Risk for Akathisia in Patients Treated With Antipsychotics: A Systematic Review and Meta-Analysis of Cross-Sectional Studies. — Schoretsanitis G, Nikolakopoulou A, Guinart D, Correll CU, Kane JM. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology. 2020.

19. Serum Iron Levels in Schizophrenic Patients With or Without Akathisia. — Kuloglu M, Atmaca M, Ustündag B, et al. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology. 2003.

20. Restless Legs Syndrome, Neuroleptic-Induced Akathisia, and Opioid-Withdrawal Restlessness: Shared Neuronal Mechanisms?. — Ferré S, Winkelman JW, García-Borreguero D, et al. Sleep. 2024.

21. The Epidemiology of Drug-Induced Akathisia: Part I. Acute Akathisia. — Sachdev P. Schizophrenia Bulletin. 1995.

22. The Epidemiology of Drug-Induced Akathisia: Part II. Chronic, Tardive, and Withdrawal Akathisias. — Sachdev P. Schizophrenia Bulletin. 1995.

23. Treatment of Hyperkinetic Movement Disorders. — Jankovic J. The Lancet. Neurology. 2009.

24. The Barnes Akathisia Rating Scale--Revisited. — Barnes TR. Journal of Psychopharmacology. 2003.

25. Risperidone Versus Placebo for Schizophrenia. — Rattehalli RD, Zhao S, Li BG, et al. The Cochrane Database of Systematic Reviews. 2016.

26. The Assessment and Treatment of Antipsychotic-Induced Akathisia. — Pringsheim T, Gardner D, Addington D, et al. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2018.

27. Switching Antipsychotics Versus Continued Current Treatment in People With Non-Responsive Schizophrenia. — Samara MT, Kottmaier E, Helfer B, et al. The Cochrane Database of Systematic Reviews. 2025.